Pelthos Therapeutics Inc. - Common Stock, par value $0.0001 per share (PTHS) Institutional Ownership

13F Institutional Holders and Ownership History from Q3 2025 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.0001 per share
Symbol
PTHS on NYSE
Shares outstanding
3,044,738
Price per share
$25.78
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
899,359
Total reported value
$27,880,129
% of total 13F portfolios
0%
Share change
+436,597
Value change
+$13,536,994
Number of holders
15
Price from insider filings
$25.78
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Pelthos Therapeutics Inc. - Common Stock, par value $0.0001 per share (PTHS) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
LIGAND PHARMACEUTICALS INC 50% 0% $145,296,959 +$7,316,652 5,189,177 +5.3% Ligand Pharmaceuticals Incorporated 06 Nov 2025
3i, LP 9.9% 0% $8,673,699 +$428,346 318,886 +5.2% 3i, LP 31 Dec 2025
Murchinson Ltd. 9.1% $7,840,000 280,000 Murchinson Ltd. 30 Sep 2025
Ikarian Capital, LLC 8.4% +38% $6,534,617 +$1,771,892 255,758 +37% Ikarian Capital, LLC 31 Dec 2025
Friedberg Ezra M 8.3% 250,121 Ezra Friedberg 01 Jul 2025

As of 31 Dec 2025, 15 institutional investors reported holding 899,359 shares of Pelthos Therapeutics Inc. - Common Stock, par value $0.0001 per share (PTHS). This represents 30% of the company’s total 3,044,738 outstanding shares.

Top 18 Institutional Shareholders

The largest institutional shareholders of Pelthos Therapeutics Inc. - Common Stock, par value $0.0001 per share (PTHS) together control 30% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Murchinson Ltd. 9.5% 289,479 +3.4% 5.6% $8,973,849
Ikarian Capital, LLC 8.4% 255,758 +310% 1% $7,928,498
BOOTHBAY FUND MANAGEMENT, LLC 2.6% 80,680 +280% 0.07% $2,501,080
J. Goldman & Co LP 2.6% 78,006 0.09% $2,418,186
VANGUARD GROUP INC 2.5% 75,020 +12% 0% $2,325,620
CANTOR FITZGERALD, L. P. 1.1% 34,990 0.03% $1,084,690
DIADEMA PARTNERS LP 0.82% 25,000 +138% 0.46% $775,000
Knott David M Jr 0.63% 19,281 +215% 0.28% $597,711
GEODE CAPITAL MANAGEMENT, LLC 0.45% 13,625 +32% 0% $422,375
MILLENNIUM MANAGEMENT LLC 0.36% 11,057 0% $342,767
Pale Fire Capital SE 0.27% 8,100 0.03% $251,100
Persistent Asset Partners Ltd 0.2% 6,007 +150% 0.09% $186,217
Steward Partners Investment Advisory, LLC 0.06% 1,910 0% 0% $59,210
UBS Group AG 0.01% 434 +217% 0% $13,454
BANK OF AMERICA CORP /DE/ 0% 12 +9.1% 0% $372
JPMORGAN CHASE & CO 0% 0 -100% $0
Tower Research Capital LLC (TRC) 0% 0 -100% $0
CITIGROUP INC 0% 0 -100% $0

Institutional Holders of Pelthos Therapeutics Inc. - Common Stock, par value $0.0001 per share (PTHS) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 899,359 $27,880,129 +$13,536,994 $31.00 15
2025 Q3 462,762 $12,957,336 +$12,957,336 $28.00 14